Glucose abnormalities detected by continuous glucose monitoring are common in young children with Cystic Fibrosis

Patients with Cystic Fibrosis-related diabetes (CFRD) have poorer lung function than those who do not have CFRD [1], and their lung function begins to decline several years prior to the development and diagnosis of fulminant diabetes [2]. CFRD is conventionally diagnosed using the Oral Glucose Tolerance Test (OGTT) but even when the OGTT is normal, patients with CF may still demonstrate elevated glucose levels on continuous glucose monitoring (CGM) [3,4]. Using a subcutaneous probe, CGM devices record interstitial fluid glucose levels over several days.
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Tags: Short Communication Source Type: research

Related Links:

Cystic-fibrosis-related diabetes (CFRD) represents one of the most frequent extra pulmonary complications of CF. It is associated with worse clinical outcomes and higher mortality rates [1,2].
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Source Type: research
Klin Padiatr DOI: 10.1055/a-1117-3771 Background Oral glucose tolerance (OGT) deteriorates progressively in cystic fibrosis (CF). Clinical registries provide a unique basis to study real-world data. Patients &methods OGT tests (OGTTs) documented in the German CF-registry in 2016 were classified according WHO, modified by ADA: normal glucose tolerance (NGT), indeterminate glycaemia (INDET), impaired fasting glucose (IFG), impaired glucose tolerance (IGT), IFG+IGT, diabetes mellitus (DM). To study the association with lung function, multivariable regression adjusted for age, sex, and CFTR mutation was performed. Results ...
Source: Klinische Padiatrie - Category: Pediatrics Authors: Tags: Original Article Source Type: research
DiscussioniCBT might implicate novel ways to increase the access to evidence-based interventions in this specific population. The distinct focus on effectiveness and cost-effectiveness of youthCOACHCD in patients with chronic somatic conditions, as well as intervention safety, will most likely provide important new insights in the field of paediatric e-mental health. A particular strength of the present study is its implementation directly into routine collaborative health care. As such, this study will provide important insights for health care policy and stakeholders and indicate how iCBT can be integrated into existing ...
Source: Trials - Category: Research Source Type: clinical trials
Basel, 3 March 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to Esbriet ® (pirfenidone) for adults with unclassifiable interstitial lung disease (uILD). The designation was granted based on data from a Phase II trial, which studied the efficacy and safety of Esbriet in uILD[1]. The study represented the first randomised controlled trial to exclusively enroll patients with progressive fibrosing uILD.“Today’s milestone for Esbriet builds on our continued commitment to improving the standard of care ...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
Cystic fibrosis (CF) is classically characterized by a progressive obstructive pulmonary disease and pancreatic exocrine insufficiency [1]. It is primarily the progressive respiratory decline that leads to an early mortality for those with CF. There are many other co-morbidities, such as cystic fibrosis-related diabetes (CFRD), that accelerates the lung decline [1]. The onset of CFRD portends a much worse prognosis and is associated with a more rapid loss of lung function, more frequent pulmonary exacerbations and ultimately an increase in mortality due to respiratory failure [2,3].
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Tags: Original article Source Type: research
;llertz A Abstract The release and absorption profile of an oral medication is influenced by the physicochemical properties of the drug and its formulation, as well as by the anatomy and physiology of the gastrointestinal (GI) tract. During drug development the bioavailability of a new drug is typically assessed in early clinical studies in a healthy adult population. However, many disease conditions are associated with an alteration of the anatomy and/or physiology of the GI tract. The same holds true for some subpopulations, such as paediatric or elderly patients, or populations with different ethnicity. The var...
Source: European Journal of Pharmaceutical Sciences - Category: Drugs & Pharmacology Authors: Tags: Eur J Pharm Sci Source Type: research
New technology, including smart phones, may be helpful in improving cystic fibrosis (CF) care and quality of life. Mobile phone technology offers the possibility of addressing a variety of challenges for individuals with CF. Phone apps may improve communication between patients and CF providers, improve social connectedness, adherence to therapy, and overall well-being. Studies in other chronic conditions such as diabetes mellitus, asthma, and COPD have demonstrated that use of mobile apps can result in significant clinical benefits [1].
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Tags: Editorial Source Type: research
Publication date: Available online 28 January 2020Source: Journal of Biomedical InformaticsAuthor(s): Akhilesh Kumar Bajpai, Sravanthi Davuluri, Kriti Tiwary, Sithalechumi Narayanan, Sailaja Oguru, Kavyashree Basavaraju, Deena Dayalan, Kavitha Thirumurugan, Kshitish K. AcharyaAbstractIn absence of periodic systematic comparisons, biologists/bioinformaticians may be forced to make a subjective selection among the many protein-protein interaction (PPI) databases and tools. We conducted a comprehensive compilation and comparison of such resources. We compiled 375 PPI resources, short-listed 125 important ones (both lists are ...
Source: Journal of Biomedical Informatics - Category: Information Technology Source Type: research
CONCLUSION: Use of the CFTR modulator lumacaftor/ivacaftor was associated with significantly lower hepatic steatosis. No association between CFRD and hepatic steatosis was found in this cohort. PMID: 31966908 [PubMed]
Source: World Journal of Hepatology - Category: Gastroenterology Tags: World J Hepatol Source Type: research
Pulmonary disease remains the most significant determinant of morbidity and mortality in cystic fibrosis (CF). Patients with CF typically experience progressive decline in lung function punctuated by pulmonary exacerbations [1], acute episodes characterized by worsened cough and sputum production and thickness, as well as decreases in pulmonary function, appetite, and weight. Over 34% of patients with CF are treated with IV antibiotics for an exacerbation each year [2]; median duration of hospitalization for these events is 9.3 days, and the median duration of IV antibiotics is 13 days [2].
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Tags: Original Article Source Type: research
More News: Child Development | Children | Cystic Fibrosis | Diabetes | Endocrinology | Respiratory Medicine